BC Week In Review | Apr 15, 2013
Company News

Novopharm Biotech board of directors update

Novopharm Biotech (TSE:NVO), Toronto, Ontario   Business: Cancer, Infectious diseases/AIDS   Appointed: Michael Tarnow, president and CEO of Creative BioMolecules Inc. (CBMI, Hopkinton, Mass.)  ...
BC Week In Review | Apr 15, 2013
Company News

Novopharm Biotech Inc. board of directors update

Novopharm Biotech Inc. (TSE:NVO), Toronto, Ontario   Business: Cancer, Infectious diseases/AIDS   Appointed: Michael Tarnow, president and CEO of Creative BioMolecules Inc. (CBMI, Hopkinton, Mass.)  ...
BioCentury | Oct 10, 2011
Product Development

Bone-free BMP

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties. BMP has been...
BioCentury | Jan 30, 2006
Product Development

Hedging on formulation

Curis Inc. doesn't think the lack of efficacy it saw in a portion of a Phase I trial of its lead basal cell carcinoma candidate targeting the hedgehog pathway has anything to do with the...
BioCentury | Jul 7, 2003
Finance

Helping push open a window

Helping push open a window Historically, the public equity market has been busy before the IPO window opened, as shown by selected U.S. financing events between the bottoms of the last two biotech bear markets...
BC Week In Review | Feb 10, 2003
Company News

EntreMed board of directors update

EntreMed Inc. (ENMD), Rockville, Md.   Business: Cancer   Appointed: Michael Tarnow as chairman, former president and CEO of Creative BioMolecules Inc.  ...
BC Week In Review | Jan 8, 2001
Clinical News

Recombinant osteogenic protein 1 regulatory update

Europe's Committee for Proprietary Medicinal Products (CPMP) issued a unanimous positive opinion to recommend marketing authorization for OP-1 in Europe. The product is a combination of OP-1 plus a collagen carrier to treat trauma related...
BC Week In Review | Jan 2, 2001
Company News

Gliatech management update

Gliatech Inc. (GLIA), Cleveland, Ohio   Business: Biomaterial/Skin/Wound   Hired: Steven Basta as president, formerly CFO and VP of finance and business development at Creative BioMolecules Inc. ; Basta replaces Robert Pinkas, who will remain...
BC Extra | Dec 18, 2000
Company News

Basta appointed president of GLIA

Gliatech , which produces therapeutics and products to improve surgical outcomes and treat neurologic disease, appointed Steven Basta president, replacing Robert Pinkas, who will remain CEO and chairman. Prior to joining GLIA, Basta was CFO and...
BC Week In Review | Sep 18, 2000
Company News

Anadys management update

Anadys Pharmaceuticals Inc., San Diego, Calif.   Business: Infectious diseases   Hired: Cheryl Lawton as SVP of Boston operations and general counsel, formerly general counsel and VP of administration at Creative BioMolecules Inc.  ...
Items per page:
1 - 10 of 97
BC Week In Review | Apr 15, 2013
Company News

Novopharm Biotech board of directors update

Novopharm Biotech (TSE:NVO), Toronto, Ontario   Business: Cancer, Infectious diseases/AIDS   Appointed: Michael Tarnow, president and CEO of Creative BioMolecules Inc. (CBMI, Hopkinton, Mass.)  ...
BC Week In Review | Apr 15, 2013
Company News

Novopharm Biotech Inc. board of directors update

Novopharm Biotech Inc. (TSE:NVO), Toronto, Ontario   Business: Cancer, Infectious diseases/AIDS   Appointed: Michael Tarnow, president and CEO of Creative BioMolecules Inc. (CBMI, Hopkinton, Mass.)  ...
BioCentury | Oct 10, 2011
Product Development

Bone-free BMP

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties. BMP has been...
BioCentury | Jan 30, 2006
Product Development

Hedging on formulation

Curis Inc. doesn't think the lack of efficacy it saw in a portion of a Phase I trial of its lead basal cell carcinoma candidate targeting the hedgehog pathway has anything to do with the...
BioCentury | Jul 7, 2003
Finance

Helping push open a window

Helping push open a window Historically, the public equity market has been busy before the IPO window opened, as shown by selected U.S. financing events between the bottoms of the last two biotech bear markets...
BC Week In Review | Feb 10, 2003
Company News

EntreMed board of directors update

EntreMed Inc. (ENMD), Rockville, Md.   Business: Cancer   Appointed: Michael Tarnow as chairman, former president and CEO of Creative BioMolecules Inc.  ...
BC Week In Review | Jan 8, 2001
Clinical News

Recombinant osteogenic protein 1 regulatory update

Europe's Committee for Proprietary Medicinal Products (CPMP) issued a unanimous positive opinion to recommend marketing authorization for OP-1 in Europe. The product is a combination of OP-1 plus a collagen carrier to treat trauma related...
BC Week In Review | Jan 2, 2001
Company News

Gliatech management update

Gliatech Inc. (GLIA), Cleveland, Ohio   Business: Biomaterial/Skin/Wound   Hired: Steven Basta as president, formerly CFO and VP of finance and business development at Creative BioMolecules Inc. ; Basta replaces Robert Pinkas, who will remain...
BC Extra | Dec 18, 2000
Company News

Basta appointed president of GLIA

Gliatech , which produces therapeutics and products to improve surgical outcomes and treat neurologic disease, appointed Steven Basta president, replacing Robert Pinkas, who will remain CEO and chairman. Prior to joining GLIA, Basta was CFO and...
BC Week In Review | Sep 18, 2000
Company News

Anadys management update

Anadys Pharmaceuticals Inc., San Diego, Calif.   Business: Infectious diseases   Hired: Cheryl Lawton as SVP of Boston operations and general counsel, formerly general counsel and VP of administration at Creative BioMolecules Inc.  ...
Items per page:
1 - 10 of 97